Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001 · see citing works

Drug Interactions with Tobacco Smoking

Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 702 · see citing works

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 617 · see citing works

KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Massarelli, E., Varella‐Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 594 · see citing works

Effects of smoking on the pharmacokinetics of erlotinib

Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2235 · Cited by 312 · see citing works

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

Li, J., Zhao, M., He, P., Hidalgo, M. M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 310 · see citing works

Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Bezjak, A., Tu, D., Seymour, L., Clark, G. M., Trajković, A., Zukin, M., Ayoub, J., Lago, S., Ribeiro, R. D. A., Gerogianni, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8073 · Cited by 295 · see citing works

Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung

Nordquist, L. T., Simon, G. R., Cantor, A. B., Alberts, W. M., & Bepler, G. (2004) · CHEST Journal · doi:10.1378/chest.126.2.347 · Cited by 228 · see citing works

Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

Johnson, J. R., Cohen, M. H., Sridhara, R., Chen, Y., Williams, G. M., Duan, J. Z., Gobburu, J. V. S., Booth, B. P., Benson, K. A., Leighton, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0790 · Cited by 224 · see citing works

Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer

Tsao, A. S., Liu, D., Lee, J. J., Spitz, M., & Hong, W. K. (2006) · Cancer · doi:10.1002/cncr.21884 · Cited by 173 · see citing works

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Clark, G. M., Zborowski, D. M., Santabarbara, P., Ding, K., Whitehead, M., Seymour, L., & Shepherd, F. A. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.022 · Cited by 158 · see citing works

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

Clark, G. M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.001 · Cited by 142 · see citing works

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128 · see citing works

Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

Clark, G. M., Zborowski, D. M., Culbertson, J. L., Whitehead, M., Savoie, M., Seymour, L., & Shepherd, F. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30414-7 · Cited by 98 · see citing works

Preclinical studies with Erlotinib (Tarceva)

Akita, R. W., & Sliwkowski, M. X. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70011-6 · Cited by 95 · see citing works

Erlotinib: Optimizing Therapy with Predictors of Response?

Goodin, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0426 · Cited by 22 · see citing works

Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer

Shepherd, F. A., Ding, K., Sakurada, A., Santos, G. D. C., Zhu, C., Seymour, L., Whitehead, M., Kamel‐Reid, S., Squire, J. A., & Tsao, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7571 · Cited by 19 · see citing works

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · see citing works

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930 · see citing works

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Reck, M., Popat, S., Reinmuth, N., Ruysscher, D. D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 679 · see citing works

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 577 · see citing works

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503 · see citing works

Impact of Specific Epidermal Growth Factor Receptor ( <i>EGFR</i> ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i> -Mutant Lung Cancer: A Meta-Analysis

Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1736 · Cited by 327 · see citing works

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303 · see citing works

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works

Drug-microbiota interactions: an emerging priority for precision medicine

Zhao, Q. C., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 296 · see citing works

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2

Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262 · see citing works

Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 240 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224 · see citing works

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

Martins, R. G., Parvathaneni, U., Bauman, J. E., Sharma, A. K., Raez, L. E., Papagikos, M. A., Yunus, F., Kurland, B. F., Eaton, K. D., Liao, J. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3299 · Cited by 205 · see citing works

Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit

Jimenez-Ruiz, C. A., Andreas, S., Lewis, K. E., Tønnesen, P., van Schayck, O. C. P., Hájek, P., Tonstad, S., Dautzenberg, B., Fletcher, M. J., Masefield, S. C., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00092614 · Cited by 195 · see citing works

Determining the optimal dose in the development of anticancer agents

Mathijssen, R. H. J., Sparreboom, A., & Verweij, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.40 · Cited by 183 · see citing works

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

Freudlsperger, C., Burnett, J. R., Friedman, J., Kannabiran, V. R., Chen, Z., & Waes, C. V. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541440 · Cited by 183 · see citing works

Smoking Cessation: An Integral Part of Lung Cancer Treatment

Cataldo, J. K., Dubey, S., & Prochaska, J. J. (2010) · Oncology · doi:10.1159/000319937 · Cited by 181 · see citing works

Clinicopathologic Features of Advanced Squamous NSCLC

Socinski, M. A., Obasaju, C. K., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.024 · Cited by 183 · see citing works

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Lee, S. M., Khan, I., Upadhyay, S., Lewanski, C. R., Falk, S. J., Skailes, G., Marshall, E., Woll, P. J., Hatton, M. Q. F., Lal, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70412-6 · Cited by 178 · see citing works

Tobacco smoking after diagnosis of cancer: clinical aspects

Jassem, J. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.01 · Cited by 168 · see citing works

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

Duruisseaux, M., Besse, B., Cadranel, J. L., Pérol, M., Mennecier, B., Bigay-Game, L., Descourt, R., Dansin, É., Audigier-Valette, C., Moreau, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15746 · Cited by 157 · see citing works

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155 · see citing works

Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer

O'Malley, M. W., King, A. N., Conte, M. L., Ellingrod, V. L., & Ramnath, N. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000191 · Cited by 139 · see citing works

Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 125 · see citing works

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 123 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110 · see citing works

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

Lankheet, N. A. G., Knapen, L. M., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000004 · Cited by 109 · see citing works

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Razak, A. R. A., Soulières, D., Laurie, S. A., Hotte, S. J., Singh, S., Winquist, E., Chia, S., Tourneau, C. L., Nguyen‐Tan, P. F., Chen, E. X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds503 · Cited by 104 · see citing works

Synthetic Pot: Not Your Grandfather’s Marijuana

Ford, B. M., Tai, S., Fantegrossi, W. E., & Prather, P. L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.003 · Cited by 102 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Josephs, D. H., Fisher, D. S., Spicer, J. F., & Flanagan, R. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318292b931 · Cited by 86 · see citing works

Effects of Tobacco Smoking and Nicotine on Cancer Treatment

Petros, W. P., Younis, I. R., Ford, J. N., & Weed, S. A. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01117 · Cited by 86 · see citing works

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 80 · see citing works

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

Thomas, F., Rochaix, P., White‐Koning, M., Hennebelle, I., Sarini, J., Benlyazid, A., Malard, L., Lefebvre, J., Chatelut, É., & Delord, J. P. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.007 · Cited by 81 · see citing works

Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review

Florou, A., Gkiozos, I., Tsagouli, S. K., Souliotis, K. N., & Syrigos, K. N. (2014) · Respiratory Care · doi:10.4187/respcare.02559 · Cited by 78 · see citing works

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

Balagula, Y., Garbe, C., Myskowski, P. L., Hauschild, A., Rapoport, B. L., Boers-Doets, C. B., & Lacouture, M. E. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04791.x · Cited by 70 · see citing works

Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors

Johnston, R. A., Rawling, T., Chan, T., Zhou, F., & Murray, M. T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059097 · Cited by 67 · see citing works

Impact of Smoking on Lung Cancer Treatment Effectiveness: A Review

Condoluci, A., Mazzara, C., Zoccoli, A., Pezzuto, A., & Tonini, G. (2016) · Future Oncology · doi:10.2217/fon-2015-0055 · Cited by 64 · see citing works

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Xu, Z., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194870 · Cited by 58 · see citing works

The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials

Hasegawa, Y., Ando, M., Maemondo, M., Yamamoto, S., Isa, S., Saka, H., Kubo, A., Kawaguchi, T., Takada, M., Rosell, R., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0285 · Cited by 56 · see citing works

The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study

Danson, S. J., Rowland, C., Rowe, R., Ellis, S. P., Crabtree, C., Horsman, J. M., Wadsley, J., Hatton, M. Q. F., Woll, P. J., & Eiser, C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2928-x · Cited by 53 · see citing works

Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands

Bart, A. G., & Scott, E. E. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005588 · Cited by 49 · see citing works

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Tiseo, M., Andreoli, R., Gelsomino, F., Mozzoni, P., Azzoni, C., Bartolotti, M., Bortesi, B., Goldoni, M., Silini, E. M., Palma, G. D., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.001 · Cited by 44 · see citing works

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

LoRusso, P. M., Boerner, S. A., & Hunsberger, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1311 · Cited by 43 · see citing works

Erlotinib

Petit-Jean, E., Buclin, T., Guidi, M., Quoix, É., Gourieux, B., Decosterd, L. A., Gairard-Dory, A., Ubeaud-Séquier, G., & Widmer, N. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000097 · Cited by 43 · see citing works

It’s never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival

Roach, M. C., Rehman, S. S. U., DeWees, T. A., Abraham, C. D., Bradley, J. D., & Robinson, C. G. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.09.005 · Cited by 41 · see citing works

Evolution of systemic therapy for advanced pancreatic cancer

Renouf, D. J., & Moore, M. J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.21 · Cited by 41 · see citing works

Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

Faehling, M., Eckert, R., Kuom, S., Kamp, T., Stoiber, K., & Schumann, C. (2010) · Oncology · doi:10.1159/000315731 · Cited by 40 · see citing works

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

Harada, T., López-Chávez, A., Xi, L., Raffeld, M. A., Wang, Y., & Giaccone, G. (2010) · Oncogene · doi:10.1038/onc.2010.545 · Cited by 38 · see citing works

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.

Gridelli, C., Maione, P., Bareschino, M. A., Schettino, C., Sacco, P. C., Ambrosio, R., Barbato, V., Falanga, M., & Rossi, A. (2010) · PubMed · Cited by 38 · see citing works

Optimizing the Management of Advanced Non-small-Cell Lung Cancer: A Personal View

Vincent, M. D. (2009) · Current Oncology · doi:10.3747/co.v16i4.465 · Cited by 36 · see citing works

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

Piperdi, B., & Perez-Soler, R. (2012) · Drugs · doi:10.2165/1163018-s0-000000000-00000 · Cited by 35 · see citing works

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

Ranson, M., Shaw, H. M., Wolf, J., Hamilton, M., McCarthy, S. P., Dean, E. J., Reid, A. H. M., & Judson, I. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1133-3 · Cited by 35 · see citing works

Smoking Cessation in Lung Cancer

Andreas, S., Rittmeyer, A., Hinterthaner, M., & Huber, R. M. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0719 · Cited by 35 · see citing works

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Boeck, S. H., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833123ed · Cited by 34 · see citing works

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

Renouf, D. J., Tang, P. A., Hedley, D. W., Chen, E., Kamel‐Reid, S., Tsao, M., Tran‐Thanh, D., Gill, S., Dhani, N. C., Au, H., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.008 · Cited by 31 · see citing works

Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review

Mitchell, P. L. R., Mok, T. S. K., Barraclough, H., Strizek, A., Lew, R. A., & Kooten, M. V. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.003 · Cited by 31 · see citing works

Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents

Duong, S., & Leung, M. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210381794 · Cited by 30 · see citing works

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy

MacLeod, A. K., Lin, D., Huang, J. T.-J., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3555 · Cited by 28 · see citing works

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

Kolesar, J., Peh, K. H., Thomas, L., Baburaj, G., Mukherjee, N., Kantamneni, R., Lewis, S. C., Pai, A., Udupa, K., Kumar, N. A. N., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01534-8 · Cited by 29 · see citing works

The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis

Li, X., Huang, C., Xie, X., Wu, Z., Tian, X., Wu, Y., Du, X., & Shi, L. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13309 · Cited by 28 · see citing works

Association of ABCB1 Polymorphisms with Erlotinib Pharmacokinetics and Toxicity in Japanese Patients with Non-Small-Cell Lung Cancer

Hamada, A., Sasaki, J.-I., Saeki, S., Iwamoto, N., Inaba, M., Ushijima, S., Urata, M., Kishi, H., Fujii, S., Semba, H., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.176 · Cited by 27 · see citing works

Effects of continued tobacco use during treatment of lung cancer

Waller, L. L., Weaver, K. E., Petty, W. J., & Miller, A. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.140 · Cited by 27 · see citing works

The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition

Elsherbiny, M. E., & Brocks, D. R. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.596204 · Cited by 26 · see citing works

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

O’Bryant, C. L., Haluska, P., Rosen, L. S., Ramanathan, R. K., Venugopal, B., Leong, S., Boinpally, R., Franke, A., Witt, K., Evans, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1733-6 · Cited by 25 · see citing works

Cigarette Smoking and Gemcitabine-Induced Neutropenia in Advanced Solid Tumors

O'Malley, M. W., Healy, P. N., Daignault, S. D., & Ramnath, N. (2013) · Oncology · doi:10.1159/000355107 · Cited by 25 · see citing works

Management strategies in pancreatic cancer

Campen, C. J., Dragovich, T., & Baker, A. F. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100254 · Cited by 24 · see citing works

Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

Pillai, V. C., Venkataramanan, R., Parise, R. A., Christner, S. M., Gramignoli, R., Strom, S. C., Rudek, M. A., & Beumer, J. H. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052100 · Cited by 24 · see citing works

Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events

Sibbald, M., Yan, A. T.-K., Huang, W., Fox, K. A. A., Gore, J. M., Steg, P. G., Eagle, K. A., Brieger, D. B., Montalescot, G., & Goodman, S. G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.026 · Cited by 23 · see citing works

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction

Das, M. S., Padda, S. K., Frymoyer, A. R., Zhou, L. Y., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.011 · Cited by 23 · see citing works

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Therapy

Lankheet, N. A. G., Schaake, E. E., Burgers, S. A., van Pel, R., Beijnen, J. H., Huitema, A. D. R., & Klomp, H. M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.012 · Cited by 23 · see citing works

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer

McGranahan, T. M., & Nagpal, S. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0466-0 · Cited by 21 · see citing works

Safety profile of new anticancer drugs

Mansi, L., Thiery-Vuillemin, A., Nguyen, T., Bazán, F., Calcagno, F., Rocquain, J., Demarchi, M., Villanueva, C., Maurina, T., & Pivot, X. B. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903530663 · Cited by 20 · see citing works

Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Phelps, M. A., Stinchcombe, T. E., Blachly, J. S., Zhao, W., Schaaf, L. J., Starrett, S. L., Wei, L., Poi, M. J., Wang, D., Papp, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.93 · Cited by 21 · see citing works

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation

Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19 · see citing works

Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use

Gougis, P., Palmieri, L., Funck‐Brentano, C., Paci, A., Flippot, R., Mir, O., & Coriat, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.006 · Cited by 20 · see citing works

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke

Waller, L. L., Miller, A. A., & Petty, W. J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.08.014 · Cited by 16 · see citing works

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes

Song, X., Varker, H., Eichelbaum, M. F., Stopfer, P., Shahidi, M., Wilson, K. L., Kaiser, R., & Finnern, H. W. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.016 · Cited by 15 · see citing works

Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay

Yamamoto, Y., Saita, T., Yamamoto, Y. L., & Shin, M. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2017.10.002 · Cited by 15 · see citing works

Pharmacokinetic Properties of Two Erlotinib 150 mg Formulations with a Genetic Effect Evaluation in Healthy Korean Subjects

Choi, H.-G., Jeon, J., Im, Y., Kim, Y., Song, E., Seo, Y.-H., Cho, S.-J., & Kim, M. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0248-4 · Cited by 14 · see citing works

“Stop Smoking!” Do We Say It Enough?

Hildebrand, J. R., & Sastry, S. (2013) · Journal of Oncology Practice · doi:10.1200/jop.2013.000890 · Cited by 14 · see citing works

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)

Faehling, M., Achenbach, J., Staib, P., Steffen, U., Tessen, H. W., Gaillard, V. E., & Brugger, W. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2649-x · Cited by 14 · see citing works

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Smit, E. F., Wu, Y.-L. L. C., Gervais, R., Zhou, C., Felip, E., Feng, J., Güçlü, S. Z., Hoiczyk, M., Dorokhova, E., Freudensprung, U., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.019 · Cited by 13 · see citing works

Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents

Visentin, M., Biason, P., & Toffoli, G. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.005 · Cited by 13 · see citing works

Thienopyridine efficacy and cigarette smoking status

Bliden, K. P., Baker, B., Nolin, T. D., Jeong, Y., Bailey, W. L., Tantry, U. S., & Gurbel, P. A. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.12.024 · Cited by 12 · see citing works

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer

Petty, W. J., Voelzke, W. R., Urbanic, J. J., Varela, V. A., Waller, L. L., Swift, C. B., Graham, R. M., Memoli, V. A., & Dragnev, K. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.004 · Cited by 12 · see citing works

Epidermal Growth Factor Receptor Pathway

Bonomi, P. (2010) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000391370.86753.90 · Cited by 12 · see citing works

Drug Exposure: Still an Excellent Biomarker

Meza–Junco, J., & Sawyer, M. B. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.58 · Cited by 11 · see citing works

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

Kumar, R., Lu, S. K., Minchom, A. R., Sharp, A., Davidson, M., Gunapala, R., Yap, T. A., Bhosle, J., Popat, S., & O'Brien, M. E. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2950-1 · Cited by 10 · see citing works

Moving Towards Molecular-Guided Treatments: Erlotinib and Clinical Outcomes in Non-Small-Cell Lung Cancer Patients

Santarpía, M., Pas, T. M. D., Altavilla, G., Spaggiari, L., & Rosell, R. (2013) · Future Oncology · doi:10.2217/fon.13.6 · Cited by 10 · see citing works

Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer

Yamamoto, Y., Iida, S., Kawanishi, T., & Fukuoka, M. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12232 · Cited by 10 · see citing works

Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions

Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10 · see citing works

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial

Gomez‐Mancilla, B., Dürsteler, K. M., Vogel, M., Herdener, M., Torrens, M., Gálvez, B. P., Gual, A., Corral, R. M., Kuper, E., Mosca, D., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adi4505 · Cited by 8 · see citing works

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations

Suzuki, H., Hirashima, T., Okamoto, N., Yamadori, T., Tamiya, M., Morishita, N., Shiroyama, T., Otsuka, T., Kitai, K., & Kawase, I. (2012) · 癌症：英文版 · doi:10.5732/cjc.012.10160 · Cited by 7 · see citing works

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis

Zheng, S., Wang, R., Zhang, Y., Pan, Y., Cheng, C., Zheng, D., Sun, Y., & Chen, H. (2016) · Cancer Medicine · doi:10.1002/cam4.764 · Cited by 7 · see citing works

Late phase 1 studies: concepts and outcomes

Benítez, J. C., Géraud, A., Texier, M., Massard, C., Paci, A., Soria, J., & Besse, B. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00467-8 · Cited by 7 · see citing works

Smoking Cessation with Lung Cancer: Not Too Little, Never Too Late!

Gemine, R. E., & Lewis, K. E. (2016) · EMJ Respiratory · doi:10.33590/emjrespir/10311510 · Cited by 7 · see citing works

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

Liao, D., Liu, Z., Zhang, Y., Liu, G., Yao, D., Cao, L., Chen, Y., Fu, Y., Yang, N., & Xiang, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00664 · Cited by 7 · see citing works

Le tabac et ses conséquences dans le cadre du traitement du cancer bronchique

Rivera, C., Rivera, S., Fabre, E., Pricopi, C., Pimpec‐Barthes, F. L., & Riquet, M. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2014.11.009 · Cited by 6 · see citing works

Rapid onset of conjunctivitis associated with overdosing of erlotinib

Sun, P., Long, J., Chen, P., He, Q., Gao, X., & Li, S. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12641 · Cited by 7 · see citing works

Phase I dose escalation pharmacokinetic study of erlotinib after failure of prior chemotherapy in patients with advanced NSCLC who continue to smoke

Hughes, A. N., O'Brien, M. E. R., Dunlop, D. J., Petty, W. J., Rankin, E. M., Chick, J., Conlan, M., Woll, P. J., Nicolson, M. C., & Price, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3597 · Cited by 3 · see citing works

PD3-2-3: Randomized phase I pharmacokinetic study of two doses of Erlotinib after failure of prior chemotherapy in patients with advanced NSCLC who continue to smoke

Woll, P. J., Petty, W. J., O'Brien, M. E. R., Rankin, E. M., Dunlop, D. J., Hughes, A. N., Nicolson, M. C., Chick, J., Boinpally, R., & Price, A. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283405.06087.13

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke

Waller, L. L., Miller, A. A., & Petty, W. J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.08.014 · Cited by 16 · see citing works

Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC.

Waller, L. L., Miller, A. A., Streer, N. P., Lovato, J. F., & Petty, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7601

An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC).

Renouf, D. J., Tang, P. A., Chen, E. X., Ho, R. H., Lourenço, L. M., Wang, L., & Moore, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4056